<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840512</url>
  </required_header>
  <id_info>
    <org_study_id>KAL05</org_study_id>
    <nct_id>NCT03840512</nct_id>
  </id_info>
  <brief_title>An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)</brief_title>
  <official_title>A Phase 2a, Open-label, Multicenter, Study to Evaluate the Pharmacokinetic (PK), Safety and Efficacy of Multiple Doses of Cannabidiol for the Prevention of aGVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kalytera Therapeutics Israel, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kalytera Therapeutics Israel, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile,&#xD;
      safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host&#xD;
      Disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study contains 3 cohorts of 12 participants each: All participants will be orally&#xD;
      administered for 105 days with CBD at doses of 75, 150 or 300 mg (PO) BID for the prevention&#xD;
      of acute GVHD (aGVHD) following allogeneic HSCT.&#xD;
&#xD;
      In addition to the study drug, all participants will receive standard aGVHD prophylaxis&#xD;
      consisting of a calcineurin inhibitor (cyclosporine or tacrolimus) and a short course of&#xD;
      methotrexate (MTX). After completion of 105 treatment days, the participant will be&#xD;
      followed-up until day 180.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) and serious adverse events (SAEs) Reporting</measure>
    <time_frame>Up to day 180</time_frame>
    <description>All AEs will be recorded, whether considered minor or serious, drug-related or not</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of aGVHD at day 100 post-transplant</measure>
    <time_frame>First 100 days after transplant</time_frame>
    <description>Cumulative Incidence of Grade B-D aGvHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - Cmax</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile - Cmax - Maximum Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - Tmax</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile - Tmax - time to reach maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - Tlag</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile - Tlag - Absorption lag-time defined as the time of the first concentration ≥ Limit of Quantitation (LOQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - AUC0-t</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile - AUC0-t - area under the plasma concentration-time curve (AUC0-t) up to the last quantifiable concentration (LOQ) from time of administration (t=0) up to the selected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - λz</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile: λz - Elimination rate constant determined by linear regression of the terminal points of the ln-linear plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - T1/2</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile: T1/2 - Terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - AUC0-∞</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile: AUC0-∞ - area under the plasma concentration-time curve extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of aGVHD at day 180 post-transplant</measure>
    <time_frame>Day 180 post-transplant</time_frame>
    <description>Cumulative Incidence of Grade 2-4 aGvHD</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Prevention aGVHD</condition>
  <arm_group>
    <arm_group_label>Oral CBD 75 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral CBD 150 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral CBD 300 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).&#xD;
Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin.</description>
    <arm_group_label>Oral CBD 150 BID</arm_group_label>
    <arm_group_label>Oral CBD 300 BID</arm_group_label>
    <arm_group_label>Oral CBD 75 BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any malignant hematological disease in CR or Myelodysplastic Syndrome (MDS)&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Karnofsky Score (KS) ≥ 60%&#xD;
&#xD;
          4. HSCT-Comorbidity Index (HSCT-CI) score ≤ 3&#xD;
&#xD;
          5. No major organ dysfunction&#xD;
&#xD;
          6. Myeloablative or reduced intensity conditioning regimen&#xD;
&#xD;
          7. Matched (7/8 or 8/8) unrelated donor&#xD;
&#xD;
          8. Peripheral blood stem cell graft&#xD;
&#xD;
          9. Female subjects of childbearing potential must use a medically accepted method of&#xD;
             contraception and must agree to continue use of this method for the duration of the&#xD;
             study and for the follow-up time period. Acceptable methods of contraception include&#xD;
             abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal&#xD;
             contraceptive (oral, transdermal, implanted, and injected) in conjunction with a&#xD;
             barrier method.&#xD;
&#xD;
         10. Male subjects with partners of childbearing potential must agree to use adequate&#xD;
             contraception (barrier method or abstinence) during the study.&#xD;
&#xD;
         11. Subject's written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Malignant hematological disease other than MDS, not in CR&#xD;
&#xD;
          2. Myelofibrosis&#xD;
&#xD;
          3. Allogeneic transplantation from a matched or mismatched sibling donor&#xD;
&#xD;
          4. Cord blood transplantation&#xD;
&#xD;
          5. Positive serology for HIV&#xD;
&#xD;
          6. Serious psychiatric or psychological disorders&#xD;
&#xD;
          7. Any uncontrolled infection at time of registration&#xD;
&#xD;
          8. Active consumption of illicit drugs (such as: Crack cocaine, Heroin, Methamphetamines,&#xD;
             Cocaine, Bath Salts, Amphetamines, Methadone, Benzodiazepine, Ecstasy)&#xD;
&#xD;
          9. Use of Cannabis and/or its derivatives fourteen days prior to HSCT and for the&#xD;
             duration of study participation&#xD;
&#xD;
         10. Uncontrolled hepatitis B or active hepatitis C infection.&#xD;
&#xD;
         11. QTc&gt;450ms per Fridericia's correction and Impaired cardiac function or clinically&#xD;
             significant cardiac diseases&#xD;
&#xD;
         12. Inadequate renal function defined as measured creatinine clearance &gt; 2.0 mg/dl&#xD;
&#xD;
         13. Liver enzymes: ALT and AST &gt; 3x upper limit of normal&#xD;
&#xD;
         14. Pregnancy or breastfeeding ((positive serum β-HCG 7 days before first dose)&#xD;
&#xD;
         15. Treatment with another investigational drug, biological agent, or device within 30&#xD;
             days of first dose, or investigational cell therapy within 6 months of first dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney - The Kinghorn Cancer Centre</name>
      <address>
        <city>Sydney</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care - Bone Marrow Transplantation Unit</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center - Bone Marrow Transplantation Department, Cancer Immunotherapy and Immunobiology Research Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davidof Cancer Center, Beilinson hospital, Rabin medical center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center - Bone Marrow Transplantation Unit</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 10, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

